Trinity Delta view: Although a small patient population, these highly impressive data from the SCOPE study effectively demonstrate the concept of using the SCIB vaccine in combination with CPIs. The strength of the results mean the second stage of the study, treating a further 27 patients (bringing the total to 43), has a 90% probability of success. In parallel, a new patient cohort will examine the same CPI doublet in combination with iSCIB1+, which offers broader patient applicability and greater potency. Data from these is expected during H124 and, subject to funding, will guide a pivotal Phase II/III registration programme. The Phase II part of this study should take 18 months and the power of these results suggest industry interest will be significant. The ImmunoBody therapeutic vaccine is one of Scancell’s four platforms, with the Moditope vaccine expected to deliver top-line Modi-1 CPI combination results during 2024 and the antibody platforms, GlyMab (anti-glycan mAbs) and AvidiMab, likely to see out-licencing deals too. Our Scancell rNPV valuation is £300.1m, or 36.7p/share.
